Last reviewed · How we verify
DTwP-HepB-Sabin IPV-Hib
At a glance
| Generic name | DTwP-HepB-Sabin IPV-Hib |
|---|---|
| Sponsor | LG Chem |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series (PHASE2, PHASE3)
- Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DTwP-HepB-Sabin IPV-Hib CI brief — competitive landscape report
- DTwP-HepB-Sabin IPV-Hib updates RSS · CI watch RSS
- LG Chem portfolio CI